Marker Therapeutics MRKR Stock
Marker Therapeutics Price Chart
Marker Therapeutics MRKR Financial and Trading Overview
| Marker Therapeutics stock price | 3.98 USD |
| Previous Close | 2.43 USD |
| Open | 2.4 USD |
| Bid | 0 USD x 1100 |
| Ask | 0 USD x 900 |
| Day's Range | 2.4 - 2.6 USD |
| 52 Week Range | 0.67 - 6.6 USD |
| Volume | 163.17K USD |
| Avg. Volume | 830.47K USD |
| Market Cap | 21.82M USD |
| Beta (5Y Monthly) | 0.851056 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.38 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 40 USD |
MRKR Valuation Measures
| Enterprise Value | 22.47M USD |
| Trailing P/E | N/A |
| Forward P/E | -0.7294117 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 1.7069659 |
| Price/Book (mrq) | 1.3709232 |
| Enterprise Value/Revenue | 1.758 |
| Enterprise Value/EBITDA | -1.013 |
Trading Information
Marker Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.851056 |
| 52-Week Change | -8.14% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 6.6 USD |
| 52 Week Low | 0.67 USD |
| 50-Day Moving Average | 1.39 USD |
| 200-Day Moving Average | 2.61 USD |
MRKR Share Statistics
| Avg. Volume (3 month) | 830.47K USD |
| Avg. Daily Volume (10-Days) | 366.08K USD |
| Shares Outstanding | 8.8M |
| Float | 6.64M |
| Short Ratio | 0.04 |
| % Held by Insiders | 12.81% |
| % Held by Institutions | 22.62% |
| Shares Short | 78.85K |
| Short % of Float | 1.25% |
| Short % of Shares Outstanding | 0.89% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:10 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -195.46% |
| Operating Margin (ttm) | -197.15% |
| Gross Margin | -106.39% |
| EBITDA Margin | -173.44% |
Management Effectiveness
| Return on Assets (ttm) | -38.0040% |
| Return on Equity (ttm) | -96.81% |
Income Statement
| Revenue (ttm) | 12.78M USD |
| Revenue Per Share (ttm) | 1.51 USD |
| Quarterly Revenue Growth (yoy) | 390.89% |
| Gross Profit (ttm) | -17125779 USD |
| EBITDA | -22172276 USD |
| Net Income Avi to Common (ttm) | -24987762 USD |
| Diluted EPS (ttm) | -2.88 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 6.4M USD |
| Total Cash Per Share (mrq) | 0.73 USD |
| Total Debt (mrq) | 7.49M USD |
| Total Debt/Equity (mrq) | 47.06 USD |
| Current Ratio (mrq) | 2.097 |
| Book Value Per Share (mrq) | 1.809 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -20634386 USD |
| Levered Free Cash Flow (ttm) | -15289563 USD |
Profile of Marker Therapeutics
| Country | United States |
| State | TX |
| City | Houston |
| Address | 4551 Kennedy Commerce Drive |
| ZIP | 77032 |
| Phone | 713-400-6400 |
| Website | https://www.markertherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 67 |
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma and selected solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia (AML) and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing MT-401, which is in Phase 2 clinical trial for the treatment of post-transplant AML; MT-401-OTS for the treatment of AML; and MT-601 for the treatment of pancreatic cancer and lymphoma. Marker Therapeutics was founded in 1999 and is headquartered in Houston, Texas.
Q&A For Marker Therapeutics Stock
What is a current MRKR stock price?
Marker Therapeutics MRKR stock price today per share is 3.98 USD.
How to purchase Marker Therapeutics stock?
You can buy MRKR shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Marker Therapeutics?
The stock symbol or ticker of Marker Therapeutics is MRKR.
Which industry does the Marker Therapeutics company belong to?
The Marker Therapeutics industry is Biotechnology.
How many shares does Marker Therapeutics have in circulation?
The max supply of Marker Therapeutics shares is 8.92M.
What is Marker Therapeutics Price to Earnings Ratio (PE Ratio)?
Marker Therapeutics PE Ratio is now.
What was Marker Therapeutics earnings per share over the trailing 12 months (TTM)?
Marker Therapeutics EPS is -1.38 USD over the trailing 12 months.
Which sector does the Marker Therapeutics company belong to?
The Marker Therapeutics sector is Healthcare.
Marker Therapeutics MRKR included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16920.58 USD — |
-0.58
|
6.33B USD — | 16873.97 USD — | 16989.6 USD — | — - | 6.33B USD — |
| NASDAQ HealthCare IXHC | 967.78 USD — |
-1.12
|
— — | 964.91 USD — | 969.79 USD — | — - | — — |
- {{ link.label }} {{link}}